Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LAS190792 Dose 1 · 1 trial · 2 indications
Adverse events (AEs) are any unfavorable and unintended medical occurrence during the subject's participation in the study (including deterioration of a pre-existing medical condition, an abnormal value in a laboratory assessment, an ECG abnormality, a 12-lead 24-hour ECG-Holter abnormality, a blood pressure abnormal value, paradoxal bronchospasm or an abnormal finding in the physical examination) and will be coded using the current Medical Dictionary for Regulatory Activities (MedDRA).
Trough is defined as the mean of the FEV1 values obtained at 23 hours and at 24 hours after morning investigational product administration.
| Arm | Type | Description |
|---|---|---|
| LAS190792 Dose 1 (Part 1) | EXPERIMENTAL | Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI) |
| LAS190792 Dose 2 (Part 1) | EXPERIMENTAL | Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI) |
| LAS190792 Dose 3 (Part 1) | EXPERIMENTAL | Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI) |
| LAS190792 Dose 4 (Part 1) | EXPERIMENTAL | Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI) |
| LAS190792 Dose 5 (Part 1) | EXPERIMENTAL | Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI) |
| LAS190792 Dose 6 (Part 1) | EXPERIMENTAL | Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI) |
| Placebo (Part 1) | PLACEBO_COMPARATOR | Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI) |
| LAS190792 Dose 1 (Part 2) | EXPERIMENTAL | Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI) |
| LAS190792 Dose 2 (Part 2) | EXPERIMENTAL | Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI) |
| Tiotropium 18 μg | ACTIVE_COMPARATOR | Single dose, oral inhalation by HandiHaler® single-dose DPI |
| Indacaterol 150 μg | ACTIVE_COMPARATOR | Single dose, oral inhalation by Breezhaler® single-dose DPI |
| Placebo (Part 2) | PLACEBO_COMPARATOR | Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI) |
| Name | Type | Description |
|---|---|---|
| LAS190792 Dose 1 | DRUG | - |
| LAS190792 Dose 2 | DRUG | - |
| LAS190792 Dose 3 | DRUG | - |
| LAS190792 Dose 4 | DRUG | - |
| LAS190792 Dose 5 | DRUG | - |
| LAS190792 Dose 6 | DRUG | - |
| LAS190792 Dose 1 (Part 2) | DRUG | - |
| LAS190792 Dose 2 (Part 2) | DRUG | - |
| Tiotropium 18 μg | DRUG | - |
| Indacaterol 150 μg | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria (PART 1): * Adult male subjects aged 18 to 70 years * Body mass index (BMI) 18.5 to 30 kg/m2 at screening * Clinical diagnosis of mild persistent asthma (according to GINA guidelines) for at least 6 months prior to screening * Ability to change current asthma therapy, to disconti...
LAS190792 Dose 1 is an investigational small molecule being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
LAS190792 Dose 1 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The drug is in Phase 1 clinical development for the treatment of COPD.
LAS190792 Dose 1 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved for commercial use. The drug is being studied for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
LAS190792 Dose 1 has been studied in one completed Phase 1 clinical trial with the identifier NCT02059434. This trial was a two-part pharmacokinetic and pharmacodynamic study in patients with asthma and COPD, conducted in the United Kingdom with 55 participants.
LAS190792 Dose 1 is a specific dose of the drug LAS190792. The clinical trial NCT02059434 studied LAS190792 in patients with asthma and COPD, and the dose is being evaluated for its safety and pharmacological effects in these conditions.